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screening. METHODS: A Markov model based on the natural
history of HPV and cervical cancer (CC) was developed to simu-
late transitions between health states (normal, HPV infection,
Cervical Intraepithelial Neoplasia (CIN) stages 1–3, CC stages
1–4, and death) in the presence of the current opportunistic
screening practices in Spain. The model was calibrated to Spanish
epidemiological endpoints: age-speciﬁc HPV and CIN preva-
lence, and age-speciﬁc CC incidence and mortality. Spanish data
was used to inform observed costs, screening and treatment
practices in Spain. Published efﬁcacy rates were used for the
HPV-16/18 vaccine including protection against non-vaccine
oncogenic HPV types (such as efﬁcacy against HPV-31 and -45).
RESULTS: Assuming the screening practices remain unchanged,
vaccinating all 12-year old girls would result in 79.1% and
79.5% decreases in the number of CC cases and deaths, respec-
tively. Vaccination would also produce substantial reductions in
the number of repeat screening tests due to abnormal cytology
and treatments for cervical dysplasia, which would partially
offset the cost of the vaccine. The introduction of Cervarix™ in
the current screening setting was predicted to result in an incre-
mental cost effectiveness ratio (ICER) of €31,749 per quality
adjusted life year (QALY) gained, when discounting at 3% for
costs and outcomes. Discounting at 4% for costs and 1.5% for
outcomes resulted in an ICER of €14,707 per QALY gained.
CONCLUSIONS: Universal vaccination with Cervarix™ for
12-year old girls within the current screening setting in Spain, is
predicted to be a cost-effective method of reducing precancerous
cervical lesions, cervical cancer incidence and mortality.
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OBJECTIVES: To investigate the economic impact of introduc-
ing micafungin (MICA) for the treatment of systemic candida
infections (SCIs) (including invasive candidiasis and can-
didaemia) in Italy, a health economic analysis was performed
comparing MICA with liposomal amphotericin B (L-AMB).
METHODS: The model was based on data from a phase III,
randomised, double-blind trial comparing MICA with L-AMB.
The model entailed a period of 14–20 weeks from initiation of
treatment and was analysed from an Italian hospital perspective.
The analysis included hospitalisation and primary medication
costs. Unit costs of these resources were taken from Italian
costing sources. As the price for MICA was not available at the
time of analysis, the price per recommended daily dose (RDD) of
MICA (100 mg) was assumed to be equal to the price per RDD
of caspofungin (50 mg). The model endpoint was deﬁned as the
percentage of patients predicted to achieve complete or partial
clinical and mycological response after initial treatment, and be
alive after the 12-week follow-up period. The model was analy-
sed using cohort and second-order Monte Carlo (MC) simula-
tion. RESULTS: The analysis of this model shows that with
MICA 52.9% of patients were predicted to have treatment
success and survive 12 weeks after end of treatment compared
with 49.1% for L-AMB. MICA was predicted to be less expen-
sive than L-AMB costing €28,668 and €40,760 per patient,
respectively. Because of lower simulated costs and the higher
effectiveness of MICA (cost-effectiveness [C/E] ratio = €54,215)
compared with L-AMB (C/E ratio = €83,035), MICA dominates
L-AMB. The results of the MC simulation and sensitivity analy-
ses showed that MICA remained the most cost-effective option.
CONCLUSIONS: The lower costs and higher effectiveness pre-
dicted for MICA versus L-AMB in this analysis indicate that in
Italy, MICA is more cost-effective for the treatment of SCIs when
compared with L-AMB.
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OBJECTIVES: To simulate the treatment of nucleoside-naïve
HBe antigen negative CHB patients with entecavir or tenofovir
in the absence of head-to-head data for cost effectiveness com-
parison. METHODS: A hypothetical cohort of 1000 received
treatment with entecavir 0.5 mg or tenofovir 300 mg daily for
48 weeks. A patient level simulation model was developed to
estimate HBV DNA distributions, assuming a parametric dis-
tribution for baseline viral load (VL) and mean drop at 48
weeks, based on summary statistics from two RCTs; BMS
AI-463027 (entecavir) and GS 174-0102 (tenofovir). Efﬁcacy
outcomes were calibrated to the end points from both trials.
Liver complications over 10 years were projected using relative
risks for CHB progression for ﬁve HBV DNA categories
(R.E.V.E.A.L.-HBV epidemiology study). The Italian payer per-
spective was applied. Direct medical costs: drug acquisition,
associated physician visits, clinical monitoring, liver event man-
agement. All model inputs estimated from published data. Dis-
count rate: 3%. RESULTS: A simulation based on baseline VL
from the tenofovir trial, entecavir was superior to tenofovir in
mean serum HBV DNA reduction at 48 weeks, with drops of
5.0 vs 4.57 log10 copies/mL, leading to 97.8% and 91.1% of
patients reaching undetectable VL respectively. For 1000
patients, the projected number of HCC and DC events within
10 years were 36 and 5, and 71 and 13, for entecavir and
tenofovir respectively. Entecavir therapy was dominant, demon-
strating €934 saving in discounted lifetime medical costs and
QALY gain of 0.62 per patient. These estimates dropped to
€773 and 0.58 QALY respectively in a sensitivity analysis to
using the mean entecavir baseline VL, resulting in 90.1% and
82% of entecavir and tenofovir patients reaching undetectable
VL at 48 weeks respectively. CONCLUSIONS: In absence of
head-to-head data between the two agents, entecavir was pro-
jected to be a clinically and economically attractive alternative
to tenofovir in this patient population.
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OBJECTIVES: Viral bronchiolitis is the most frequent cause of
infection of the lower respiratory tract among children younger
than 12 months old, with frequent hospitalizations and rare
deaths. Palivizumab, a high cost drug, is approved for VSR
prophylaxis. Our objective was to assess the cost-effectiveness
of palivizumab in the prophylaxis of RSV bronchiolitis in high
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risk patients. METHODS: A decision analysis model compar-
ing the prophylactic administration of palivizumab versus no
administration was built. The analysis included premature
babies 32 gestational age (GA) with/without bronchopulmo-
nary dysplasia, premature babies 35 GA with/without bron-
chopulmonary dysplasia, premature babies 35 GA without
bronchopulmonary dysplasia, premature babies 32–35 GA
without bronchopulmonary dysplasia, and children younger
than 5 years with congenital heart disease. We used the payer
perspective and a temporal horizon of 1 year and the life
expectancy of the babies. The model included administration of
palivizumab (3 doses), hospitalization and death. Efﬁcacy data
came from a systematic review. Direct costs included drug
acquisition and administration, and hospitalization. Determin-
istic univariant sensitivity analyses were performed. RESULTS:
ICER ranged between €17,337.10 and €68,380.77/hospitali-
zation avoided, and between €166,721.18 and €1,476,568.81/
LYG. Considering 5 doses of palivizumab, ICER ranged
between €28,895.16 and €113,967.95/ hospitalization avoided,
and €310,743.34 and €1,073,111.85/LYG. CONCLUSIONS:
The results of the analysis showed that the prophylactic admin-
istration of palivizumab is not efﬁcient preventing hospitaliza-
tions and avoiding deaths. The ICER to prevent one
hospitalization is much higher than the cost of a hospitalization
itself. The ICER per LYG is much higher than commonly
accepted thresholds. These results are consistent with previ-
ously published studies. Differences existed with studies that
included treatment costs of future related diseases, a fact not
supported by current available scientiﬁc evidence.
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OBJECTIVES: Implementation of an HPV vaccine has been pre-
dicted to reduce the burden of cervical cancer. In this research, we
estimated the costs and beneﬁts of the addition of Human Pap-
illoma Virus (HPV) type 16, 18 vaccination to the Dutch cervical
cancer screening program. METHODS: In order to calculate the
cost-effectiveness ratio (ICER) for vaccination Dutch girls against
HPV, we adapted an existing HPV Markov model to The Neth-
erlands. For the base-case analysis, we assumed 100% vaccine
coverage among Dutch 12-year-old girls, a vaccine price of €100
per dose, that no booster vaccination was needed, and cross-
protection against the HPV subtypes 31 and 45 was taken into
account. The model was calibrated according to Dutch incidence
and mortality data. Sensitivity analysis was used to estimate the
robustness and impact of some parameters on cost-effectiveness
ratio. RESULTS: We estimated that the addition of an HPV
vaccine to the Dutch cervical cancer screening program would
cost €31.5 million annually. However implementation of this
vaccination would reduce CIN and cervical cancer costs by €11.5
million and would save 2907 life years (non-discounted). These
ﬁgures give a discounted (4% costs, 1.5% outcomes) ICER of
€22,700 per life year gained (€18,500/QALY). According to
sensitivity analysis, the ICER is sensitive for vaccine price and
discount rate. CONCLUSIONS: Immunization of 12-year-old
Dutch girls against HPV infection is a cost-effective strategy in
protection of these girls against cervical cancer. Although we
made several assumptions, our estimated ICER corresponds with
previous analyses relating to cervical cancer vaccination.
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OBJECTIVES: To assess the cost-effectiveness of mass vaccina-
tion for varicella, based on a dynamic model of varicella and
zoster. METHODS: Priorix-Tetra™ (GlaxoSmithKline Biologi-
cals’ measles, mumps, rubella, and varicella: MMRV) vaccina-
tion is highly protective against measles, mumps, rubella and
varicella and can result in fewer zoster cases in the long term.
Replacing Priorix™ (GlaxoSmithKline Biologicals’ measles,
mumps, rubella; MMR) with Priorix-Tetra™ can sustain a high
vaccine coverage rate for varicella, which might be harder to
achieve with monovalent varicella vaccination. The outcome of
varicella mass vaccination was predicted using a dynamic trans-
mission model. French costs and event rates per varicella and
zoster case (hospitalisation, GP visits, complications and deaths)
were applied. Probabilistic sensitivity analysis was performed.
RESULTS: Mass vaccination decreased varicella incidence from
12,571 to 4,859 per million person-years. After a slight initial
increase, zoster incidence decreased as the vaccinated cohort
aged. The large reduction in varicella and zoster cases with
Priorix Tetra™ resulted in a signiﬁcant number of complications
avoided and more QALYs saved, versus MMR. The direct costs
of vaccination in year 1 were €302,840 with MMRV versus
€207,906 with MMR, due to the higher cost of the tetravalent
vaccine. Signiﬁcant indirect cost savings were achieved compared
with MMR; from €52,043 in year 1 to €1.7 million every year in
the post-vaccination steady-state situation (reached after around
30 years). The cumulative direct cost/QALY saved was €83,000
(year 1, coverage ª20% of MMR replaced), €18,100 (year 5,
coverage ª100% of MMR) and €14,150 (year 30). MMRV was
the dominant cost-effective strategy compared with MMR when
indirect costs were included. CONCLUSIONS: Vaccination with
MMRV provided more QALYs, resulted in fewer complications
and deaths, and reduced direct and indirect costs (excluding
vaccine costs) when compared with vaccination with MMR. The
cost/QALY was €83,000 in year one, dropping to below €20,000/
QALY thereafter.
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OBJECTIVES: The aim of the study is to estimate the cost-
effectiveness of itraconazole in the treatment of invasive
aspergillozis compared to current alternatives (Amphotericin-B,
vorikonazol) using health economic modeling techniques in
Turkish setting. METHODS: Model: In order to evaluate cost-
effectiveness of itraconazole, a decision-tree modelling is used.
The time horizon considered in the model is 12 weeks. The
study is performed from the health care payer perspective.
Patient group: Immunecompromised patients with diagnosis of
invasive aspergillosis. Data sources: The clinical data are
acquired from published clinical studies. Resource use data are
based on expert panel. Prices of medications, institutional dis-
count rates and other costs related to the treatment are
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